Detalhe da pesquisa
1.
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol
; 21(1): 33-43, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31838010
2.
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
Breast Cancer Res
; 22(1): 120, 2020 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33138866
3.
First reported double drug-drug interaction in a cancer renal patient under everolimus treatment: therapeutic drug monitoring and review of literature.
Eur J Med Res
; 28(1): 202, 2023 Jun 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37381038
4.
Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study.
Front Oncol
; 11: 645026, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34307126
5.
Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication.
Ther Adv Med Oncol
; 11: 1758835919833867, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31205497